Thr12

Site Information
EQVKPLEtSsSKVKA SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 7998507

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Relevant cell line - cell type - tissue:	Jurkat (T lymphocyte) ( 1 , 2 , 3 , 4 , 5 )

References
1	Possemato A (2009) CST Curation Set: 6383; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]XXp[ST] Curated Info
2	Possemato A (2009) CST Curation Set: 6361; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
3	Possemato A (2009) CST Curation Set: 6370; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info
4	Possemato A (2009) CST Curation Set: 6360; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:p[ST] Curated Info
5	Possemato A (2009) CST Curation Set: 6368; Year: 2009; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSP Curated Info